BackCorbus Pharmaceuticals Holdings Overview

Corbus Pharmaceuticals Holdings Current Cash

Track Corbus Pharmaceuticals Holdings's current cash ($26M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$26.05M
37.81% YoYΔ $7.15M vs prior year quarter

Peer average

Loading

Corbus Pharmaceuticals Holdings Current Cash History

Loading

Corbus Pharmaceuticals Holdings vs. peers: Current Cash Comparison

Loading

Corbus Pharmaceuticals Holdings Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Corbus Pharmaceuticals Holdings (CRBP) FAQ

The latest current cash for CRBP is $26M as of March 2026. That compares with $19M in the prior-year period — up 37.8% year over year. Investors often review this figure alongside Corbus Pharmaceuticals Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRBP's current cash moved from $19M to $26M — a 37.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Corbus Pharmaceuticals Holdings's operating scale or balance-sheet position.

A current cash figure of $26M for CRBP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CRBP's current cash ($26M), review year-over-year change from $19M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Corbus Pharmaceuticals Holdings's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.